A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Completed · Phase 2 · Has a placebo group

Conditions studied: Adjunctive Treatment of Major Depressive Disorder

In brief

The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy. The objective of the study is to assess CLE-100 for the treatment of MDD in participants currently treated with standard antidepressant therapy.

Key facts

Study ID
NCT04103892
Run by
Clexio Biosciences Ltd.
People needed
146
Starts
2019-09-05
Expected to finish
2022-10-05
Last updated by the study team
2025-10-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.